STOCK TITAN

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in the Jefferies Healthcare Conference in New York City on June 9, 2022. CEO Dr. Christian Itin will engage in a Fireside Chat from 9:00 to 9:30 am ET. The company will also hold one-on-one investor meetings at the event. An audio webcast of the Fireside Chat will be available on Autolus' website, with an archived version accessible for a limited period post-conference. Autolus specializes in programmed T cell therapies aimed at treating various cancers.

Positive
  • None.
Negative
  • None.

LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending the Jefferies Healthcare Conference at the Marriott Marquis in New York City. Autolus’ Chief Executive Officer Dr. Christian Itin will participate in a Fireside Chat on Thursday, June 9 at 9.00 – 9.30 am ET (2:00 pm – 2.30 pm BST) and the Company will also be attending one-on-one investor meetings at the event.

An audio webcast of the Fireside Chat will be on the Events section of the Autolus website. An archived version will also be available through the Company’s website for a limited time following the conference.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.

Contact:

Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com


FAQ

When is Autolus Therapeutics participating in the Jefferies Healthcare Conference?

Autolus Therapeutics will attend the Jefferies Healthcare Conference on June 9, 2022.

Who will represent Autolus at the Jefferies Healthcare Conference?

CEO Dr. Christian Itin will represent Autolus at the conference.

What time will the Fireside Chat take place at the conference?

The Fireside Chat will take place from 9:00 to 9:30 am ET.

Where can I find the audio webcast of Autolus' Fireside Chat?

The audio webcast will be available on the Events section of Autolus' website.

What type of therapies does Autolus Therapeutics develop?

Autolus develops next-generation programmed T cell therapies for cancer treatment.

Autolus Therapeutics plc American Depositary Share

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Stock Data

798.37M
213.36M
18.09%
76.21%
2.7%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LONDON